Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPiCS-04 trial of sacituzumab govitecan versus taxane chemotherapy in previously treated advanced urothelial carcinoma
MOH_2021-10-12_010201Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Sep 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sacituzumab govitecan in transitional cell carcinoma (TCC) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Overall survival. Started Sep 2021; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on MOH_2021-10-12_010201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-10-12_010201.